Connection

Ali Rizvi to Hypoglycemic Agents

This is a "connection" page, showing publications Ali Rizvi has written about Hypoglycemic Agents.
Connection Strength

3.898
  1. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020 08; 109:154295.
    View in: PubMed
    Score: 0.554
  2. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther. 2015; 15(10):1391-7.
    View in: PubMed
    Score: 0.394
  3. Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opin Pharmacother. 2015 Feb; 16(3):281-4.
    View in: PubMed
    Score: 0.378
  4. Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents. Metab Syndr Relat Disord. 2014 Feb; 12(1):1-10.
    View in: PubMed
    Score: 0.351
  5. Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opin Ther Targets. 2013 Jul; 17(7):739-42.
    View in: PubMed
    Score: 0.339
  6. Impact of comprehensive diabetes specialty care in the management of older adults with stage 3 or 4 nephropathy. South Med J. 2009 Sep; 102(9):985.
    View in: PubMed
    Score: 0.262
  7. Type 2 diabetes: epidemiologic trends, evolving pathogenetic [corrected] concepts, and recent changes in therapeutic approach. South Med J. 2004 Nov; 97(11):1079-87.
    View in: PubMed
    Score: 0.188
  8. Thiazolidinedione therapy in a patient with diabetes after cardiac transplantation. Endocr Pract. 2002 Jul-Aug; 8(4):287-91.
    View in: PubMed
    Score: 0.160
  9. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opin Drug Saf. 2022 03; 21(3):291-293.
    View in: PubMed
    Score: 0.156
  10. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
    View in: PubMed
    Score: 0.150
  11. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Res Clin Pract. 2019 Mar; 149:163-169.
    View in: PubMed
    Score: 0.126
  12. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):129-143.
    View in: PubMed
    Score: 0.126
  13. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016 Dec 03; 15(1):162.
    View in: PubMed
    Score: 0.108
  14. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab. 2015 Feb; 100(2):603-6.
    View in: PubMed
    Score: 0.094
  15. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014 Feb 22; 13:49.
    View in: PubMed
    Score: 0.089
  16. A review of the cardiovascular and anti-atherogenic effects of ghrelin. Curr Pharm Des. 2013; 19(27):4953-63.
    View in: PubMed
    Score: 0.083
  17. Perioperative management of diabetes and hyperglycemia in patients undergoing orthopaedic surgery. J Am Acad Orthop Surg. 2010 Jul; 18(7):426-35.
    View in: PubMed
    Score: 0.069
  18. Management of diabetes in older adults. Am J Med Sci. 2007 Jan; 333(1):35-47.
    View in: PubMed
    Score: 0.054
  19. Assessment and monitoring of glycemic control in primary diabetes care: monitoring techniques, record keeping, meter downloads, tests of average glycemia, and point-of-care evaluation. J Am Acad Nurse Pract. 2006 Jan; 18(1):11-21.
    View in: PubMed
    Score: 0.051
  20. An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Kaunas). 2022 Oct 17; 58(10).
    View in: PubMed
    Score: 0.041
  21. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):494-496.
    View in: PubMed
    Score: 0.035
  22. Microvascular and macrovascular effects of liraglutide. Int J Cardiol. 2019 07 01; 286:17-18.
    View in: PubMed
    Score: 0.032
  23. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018 09; 1864(9 Pt B):2814-2821.
    View in: PubMed
    Score: 0.030
  24. Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes. Diabetes Obes Metab. 2017 05; 19(5):613-614.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.